Table 2.

Summary of Recommendations

	Amino Acid PET (MET, FET, FDOPA)	FDG PET	Other PET Tracers	Oxford Level of Evidence
Target delineation for radiotherapy planning	++	−	n.a.	2
Prognostic value of PET prior to radiotherapy	++	++	n.a.	2
PET-based radiotherapy in patients with newly diagnosed gliomas	(++)	n.a.	n.a.	3
PET-based re-irradiation in patients with glioma relapse	(++)	n.a.	n.a.	3
Assessment of response to radiotherapy	++	+	(++)	2
Differentiation of radiation injury from glioma relapse	++ a	+	n.a.	2
Use of artificial intelligence for radiotherapy	(++)	n.a.	n.a.	3

Abbreviations: FDG, [¹⁸F]-2-fluoro-2-deoxy-d-glucose; FDOPA, 3,4-dihydroxy-6-[¹⁸F]-fluoro-l-phenylalanine; FET, O-(2-[¹⁸F]-fluoroethyl)-l-tyrosine; MET, [¹¹C-methyl]-l-methionine.

++ high diagnostic value; (++) high diagnostic value, but limited data available; + limited diagnostic accuracy; − not helpful; n.a. = only preliminary or no data available.

^aIncreased accuracy when using dynamic FET PET.